CryoLife, Inc. (CRY)

HEALTH CARE: HEALTH CARE SUPPLIES
SIC: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

1655 ROBERTS BOULEVARD N W KENNESAW, GA 30144

Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide.

Data as of 2021-09-19 11:51:07 -0400
Market Cap940.993 Million Shares Outstanding39.306 Million Avg 30-day Volume143.071 Thousand
P/E Ratio-81.85396 Dividend Yield EPS-0.298
Price/Sales3.36 Debt to Equity2.69 EBITDA31.386 Million
Price to Book Value3.12 Forward PE0.35 Enterprise Value1.2 Billion
Total Cash50.473 Million Current Debt58.944 Million Gross Profit186.074 Million
BETA1.00671 52-week High/Low32.34 / 16.6 Next Earnings Date2021-11-03 Price to Cash FLow (P/CF) -509.3761
Data provided by IEX Cloud
View SEC Filings from CRY instead.

View recent insider trading info

Funds Holding CRY (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CRY BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

9 Thousand total shares from 3 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HOLLOWAY JEAN F SVP, GENERAL COUNSEL

  • Officer
86,567 2021-08-31 9

MORGAN HARVEY

  • Director
97,110 2021-08-30 3

MCCALL RONALD D

  • Director
121,768 2021-08-25 4

MAIER DENNIS B VICE PRESIDENT, OPERATIONS

  • Officer
17,677 2021-08-23 9

ACKERMAN THOMAS F

  • Director
119,695 2021-06-01 1

BULLOCK JAMES

  • Director
38,446 2021-06-01 1

BEVEVINO DANIEL J

  • Director
119,860 2021-06-01 1

BURBANK JEFFREY H

  • Director
23,595 2021-06-01 1

SALVESON JON W

  • Director
99,639 2021-06-01 1

BORGSTROM MARNA P

  • Director
18,887 2021-06-01 1

DAVIS JOHN E SENIOR VP, GLOBAL SALES

  • Officer
156,537 2021-05-25 6

HORTON AMY VP, CHIEF ACCOUNTING OFFICER

  • Officer
89,282 2021-05-06 10

LEE DAVID ASHLEY EXECUTIVE VP, COO & CFO

  • Officer
299,185 2021-05-05 7

MACKIN JAMES P PRESIDENT & CEO

  • Officer
304,178 2021-04-30 5

STANTON MARSHALL S. SVP, CLINICAL & MD AFFAIR

  • Officer
9,511 2021-03-16 2

CAPPS SCOTT B VP, CLINICAL RESEARCH

  • Officer
153,203 2021-03-12 5

GREEN ANDREW M VP REGULATORY

  • Officer
0 2021-03-08 2

BARTHOLD FRANZ PETER VP, RESEARCH & DEVELOPMENT

  • Officer
12,121 2021-03-08 5

MANEY ROCHELLE L. VP, QUALITY

  • Officer
0 2021-03-08 2

SIMPSON MICHAEL S SVP, REGULATORY AFFAIRS AND QA

  • Officer
33,698 2021-03-05 4

GETZ MATTHEW A VP, HUMAN RESOURCES

  • Officer
9,514 2021-02-23 2

BOGENSCHUETZ THOMAS J VP, EMEA & GENERAL MANAGER

  • Officer
0 2020-05-05 0

SAURINI SHERRY M VP, QUALITY

  • Officer
25,084 2019-03-14 0

MCDERMID JAMES M SVP, CHRO

  • Officer
30,806 2019-03-14 0

RONALD C ELKINS

  • Director
64,843 2018-09-05 0

MATTHEWS WILLIAM ROBERT SENIOR VP, OPERATIONS, QUALITY

  • Officer
39,883 2018-03-05 0

GALE DAVID C VP, RESEARCH & DEVELOPMENT

  • Officer
77,135 2017-11-16 0

BENSON JAMES

  • Director
54,086 2017-10-02 0

ANDERSON STEVEN G FORMER EXECUTIVE CHAIRMAN

  • Officer
No longer subject to file 2015-04-09 0

FRONK DAVID VP, REGULATORY AFFAIRS

  • Officer
110,559 2015-03-07 0

ANDERSON BRUCE G. VP, US SALES &GLOBAL MARKETING

  • Officer
104,096 2015-03-07 0

LANG DAVID P. VP, INT'L SALES & MARKETING

  • Officer
73,441 2015-02-26 0

BURRIS JEFFREY W VICE PRESIDENT & GEN. COUNSEL

  • Officer
95,221 2014-08-15 0

SEERY GERALD B SR. VP, SALES AND MARKETING

  • Officer
71,999 2012-11-30 0

HEACOX ALBERT E SR. VP RESEARCH AND DEVL

  • Officer
No longer subject to file 2011-12-31 0

COOK JOHN M

  • Director
104,500 2009-06-09 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

HOLLOWAY JEAN F - Officer SVP, GENERAL COUNSEL

2021-09-01 16:14:34 -0400 2021-08-31 S 663 $26.49 d 86,567 direct -2.5709 -6.1248 0.0 1 -6.1248 6

MORGAN HARVEY - Director

2021-08-31 17:11:58 -0400 2021-08-30 G 3,645 d 50,768 direct 0.1515 -4.2787 0.1515 2 -4.2787 6

MORGAN HARVEY - Director shares owned indirectly by spouse in a revocable trust

2021-08-31 17:11:58 -0400 2021-08-30 G 3,645 a 46,342 indirect 0.1515 -4.2787 0.1515 2 -4.2787 6

MCCALL RONALD D - Director

2021-08-26 16:13:11 -0400 2021-08-25 S 5,667 $25.63 d 121,768 direct -0.7707 -0.6936 1.9268 5 -0.7707 2

MAIER DENNIS B - Officer VICE PRESIDENT, OPERATIONS

2021-08-24 17:15:22 -0400 2021-08-23 S 2,715 $25.64 d 17,677 direct -2.0842 3.8537 3.8537 6 -2.0842 2

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
CRYOLIFE INC CRY 2021-09-24 22:15:03 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 21:45:03 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 21:15:03 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 20:45:03 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 20:15:03 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 19:45:03 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 19:15:03 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 18:45:03 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 18:15:03 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 17:45:03 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 17:15:03 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 16:45:03 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 16:15:03 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 15:45:03 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 15:15:04 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 14:45:02 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 14:15:02 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 13:45:02 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 13:15:03 UTC -0.18 0.25 1400000
CRYOLIFE INC CRY 2021-09-24 12:45:03 UTC -0.18 0.25 1400000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund CRY -135.0 shares, $-2284.2 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund CRY -100.0 shares, $-1692.0 2020-03-31 N-PORT
Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio CRY -21200.0 shares, $-602080.0 2021-06-30 N-PORT
Prudential Investment Portfolios 12- PGIM QMA Large-Cap Core Equity Plus Fund CRY -1100.0 shares, $-31240.0 2021-06-30 N-PORT
FORUM FUNDS- ABSOLUTE CONVERTIBLE ARBITRAGE FUND CRY -149000.0 shares, $-4231600.0 2021-06-30 N-PORT

Elevate your investments